Short Interest in Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Declines By 88.2%

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) was the target of a significant decrease in short interest in the month of February. As of February 13th, there was short interest totaling 73,194 shares, a decrease of 88.2% from the January 29th total of 619,061 shares. Based on an average daily trading volume, of 194,119 shares, the short-interest ratio is presently 0.4 days. Approximately 5.2% of the company’s shares are short sold. Approximately 5.2% of the company’s shares are short sold. Based on an average daily trading volume, of 194,119 shares, the short-interest ratio is presently 0.4 days.

Shuttle Pharmaceuticals Trading Up 2.9%

Shuttle Pharmaceuticals stock traded up $0.03 during mid-day trading on Wednesday, hitting $1.08. The company had a trading volume of 40,545 shares, compared to its average volume of 336,616. The company has a market capitalization of $1.73 million, a price-to-earnings ratio of -0.09 and a beta of -1.02. The company’s fifty day moving average is $1.66 and its 200-day moving average is $2.56. Shuttle Pharmaceuticals has a 12-month low of $1.00 and a 12-month high of $16.05.

Hedge Funds Weigh In On Shuttle Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Ikarian Capital LLC purchased a new position in Shuttle Pharmaceuticals during the fourth quarter worth approximately $124,000. Boothbay Fund Management LLC acquired a new stake in Shuttle Pharmaceuticals in the 4th quarter valued at $37,000. Geode Capital Management LLC acquired a new stake in Shuttle Pharmaceuticals in the 4th quarter valued at $26,000. Finally, Connective Capital Management LLC purchased a new stake in Shuttle Pharmaceuticals in the 3rd quarter worth $357,000. Hedge funds and other institutional investors own 4.58% of the company’s stock.

Wall Street Analysts Forecast Growth

SHPH has been the topic of a number of analyst reports. Wall Street Zen raised Shuttle Pharmaceuticals to a “sell” rating in a research note on Saturday, November 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Shuttle Pharmaceuticals in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .